Retatrutide vs Tirzepatide vs Semaglutide

Retatrutide

28.7% vs 20.2% vs 13.7%

Maximum reported weight loss for retatrutide (68 wk), tirzepatide (72 wk), and semaglutide (72 wk) in their respective clinical programs.

Multiple sources: Lilly 2025 (TRIUMPH-4), Aronne et al. NEJM 2025 (SURMOUNT-5)

Multiple sources: Lilly 2025 (TRIUMPH-4), Aronne et al. NEJM 2025 (SURMOUNT-5)

View as image

The weight loss hierarchy among incretin-based drugs is now clear in magnitude, if not in head-to-head data: retatrutide (28.7%) > tirzepatide (20.2%) > semaglutide (13.7%). These numbers come from the drugs' best clinical trial results at their highest approved or tested doses.^[1][2] But comparing drugs across separate trials is fundamentally different from testing them against each other, and the comparison of retatrutide vs tirzepatide vs semaglutide requires more nuance than a single number can provide. For context on how retatrutide's clinical trial data emerged, the results article covers the TRIUMPH program in detail.

The Receptor Count: Why More Targets Mean More Weight Loss

The simplest framework for understanding these three drugs is receptor count. Alfaris et al. (2024) published a comprehensive review in EClinicalMedicine mapping the progression from single to dual to triple agonism.^[3]

Semaglutide activates one receptor: GLP-1. This reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion. At 2.4 mg weekly, it produces 15-17% weight loss in most trials.

Tirzepatide activates two receptors: GLP-1 and GIP. The GIP component adds a separate pathway for insulin secretion and may contribute to fat tissue remodeling. At 15 mg weekly, it produces 20-23% weight loss. How tirzepatide's dual mechanism differs from single agonists explains the pharmacology in detail.

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon component increases energy expenditure, promotes hepatic fat oxidation, and may improve body composition by shifting the metabolic balance toward fat burning. At 12 mg weekly, it produces 24-29% weight loss. How retatrutide targets all three receptors covers the triple mechanism.

Movahednasab et al. (2025) mapped this progression from a molecular perspective, showing how each additional receptor target contributes a distinct metabolic pathway that compounds the weight loss effect.^[4] The relationship is not simply additive. The glucagon receptor brings qualitatively different effects (increased energy expenditure, liver fat reduction) that the GLP-1 and GIP pathways do not provide.

The Only Head-to-Head: SURMOUNT-5

The most important comparison study to date is SURMOUNT-5, published by Aronne et al. in the New England Journal of Medicine in 2025. This was the first randomized, head-to-head trial directly comparing tirzepatide and semaglutide for obesity treatment.^[2]

At 72 weeks, tirzepatide 15 mg produced 20.2% mean weight loss versus 13.7% for semaglutide 2.4 mg. The difference (6.5 percentage points) was statistically significant and clinically meaningful. Tirzepatide achieved this with a similar gastrointestinal side effect profile to semaglutide, meaning the extra weight loss did not come at the cost of substantially worse tolerability.

Bernardi et al. (2026) conducted a network meta-analysis in the Journal of Diabetes that incorporated both direct and indirect evidence, confirming the tirzepatide advantage over semaglutide for weight reduction.^[5] They noted that retatrutide demonstrated greater absolute weight reduction compared to tirzepatide in indirect comparisons, though no direct trial data exist.

Weight Loss Numbers Side by Side

The most referenced weight loss results from each drug's clinical program:

Semaglutide 2.4 mg (Wegovy)

• STEP 1: -14.9% at 68 weeks (vs -2.4% placebo)
• SURMOUNT-5: -13.7% at 72 weeks (head-to-head vs tirzepatide)

Tirzepatide 15 mg (Zepbound)

• SURMOUNT-1: -22.5% at 72 weeks (vs -2.4% placebo)
• SURMOUNT-5: -20.2% at 72 weeks (head-to-head vs semaglutide)

Retatrutide 12 mg (investigational)

• Phase 2: -24.2% at 48 weeks (vs -2.1% placebo), curve still declining^[1]
• TRIUMPH-4: -28.7% at 68 weeks

These numbers are not directly comparable. STEP 1 and SURMOUNT-1 used placebo controls in different populations. SURMOUNT-5 is the only apples-to-apples comparison. The retatrutide phase 2 was shorter (48 weeks) than the comparators (68-72 weeks), and the weight curve had not plateaued, making the 24.2% number a floor, not a ceiling.

Sinha et al. (2025) conducted a Bayesian network meta-analysis across all GLP-1 RA, dual agonist, and retatrutide trials, ranking them for weight loss efficacy. The hierarchy matched expectations: retatrutide > tirzepatide > semaglutide > liraglutide.^[6]

Diabetes Outcomes: Beyond Weight

All three drugs lower HbA1c in patients with type 2 diabetes, but through somewhat different mechanisms. Semaglutide (Ozempic, 0.5-2.0 mg) was the first to demonstrate cardiovascular benefit in SUSTAIN-6 and SELECT. Tirzepatide (Mounjaro, 5-15 mg) showed superior glycemic control versus semaglutide 1 mg in the SURPASS-2 head-to-head trial, with HbA1c reductions of up to 2.5 percentage points.

Retatrutide 12 mg produced HbA1c reductions of 2.02 percentage points from a baseline of approximately 8.3% in its phase 2 diabetes trial (Rosenstock et al., 2023). The glucagon component is theoretically a liability for glucose control, since glucagon raises blood sugar, but in practice the GLP-1 and GIP agonism overwhelm this effect. The net result is glucose lowering comparable to or exceeding the dual agonist approach.

No cardiovascular outcomes trial has reported for retatrutide. Both semaglutide and tirzepatide have either completed or are running dedicated cardiovascular outcomes studies. This gap in the retatrutide dataset is relevant for patients with established cardiovascular disease, where the evidence base for semaglutide is strongest.

Safety: Does More Weight Loss Mean More Side Effects?

Fahim et al. (2025) published a comparative safety analysis of semaglutide and tirzepatide using FDA adverse event data. They found broadly similar gastrointestinal event profiles between the two drugs, though the specific patterns of nausea, vomiting, and diarrhea varied slightly in timing and severity.^[7]

Kasagga et al. (2025) conducted a comparative efficacy and tolerability review at varying doses, finding that tirzepatide's gastrointestinal events were dose-dependent but manageable with titration, similar to the semaglutide experience.^[8]

For retatrutide, the phase 2 data showed gastrointestinal events were the primary safety concern, with a dose-titration strategy (starting at 2 mg) partially mitigating nausea and vomiting.^[1] The TRIUMPH-4 phase 3 data identified dysesthesia (abnormal touch sensations) as a new side effect specific to retatrutide, affecting roughly 1 in 5 patients at the 12 mg dose, though it was described as "generally mild" and rarely led to discontinuation.

Heart rate increases were dose-dependent in retatrutide trials, peaking around 24 weeks and then declining. This pattern was not seen to the same degree with semaglutide or tirzepatide, and whether the glucagon receptor component contributes to this effect is an open question.

Munawar et al. (2025) conducted a systematic review and meta-analysis comparing tirzepatide versus semaglutide for weight loss in overweight and obese adults, finding comparable safety profiles between the two drugs with tirzepatide demonstrating superior efficacy.^[9]

Body Composition and Liver Fat

The drugs differ in what the weight loss consists of. Coskun et al. (2025) found that retatrutide reduced fat mass preferentially, with a more favorable fat-to-lean ratio than semaglutide. The glucagon receptor component likely drives this by increasing energy expenditure and hepatic fat oxidation.^[10]

Targher et al. (2025) reviewed advances in incretin-based therapy for metabolic liver disease, noting that retatrutide's liver fat reduction was dramatically greater than what semaglutide or tirzepatide achieved. In the phase 2a MASH trial, some retatrutide patients achieved complete normalization of liver fat, a result not seen with single or dual agonists.^[11]

This liver effect may become a differentiating factor beyond weight loss. For patients with MASH/MASLD, retatrutide's glucagon-mediated fat oxidation offers a pharmacological advantage that semaglutide and tirzepatide cannot match through their mechanisms. Semaglutide does reduce liver fat through weight loss and anti-inflammatory pathways, but the magnitude is smaller. Tirzepatide shows intermediate liver effects. The dose-response across the three drugs for liver fat mirrors the receptor count pattern: more targets, more liver fat reduction.

Body composition is equally important for long-term health. Patients who lose 20%+ of body weight on any of these drugs face meaningful lean mass loss if they do not actively counteract it with resistance training and adequate protein intake. Whether retatrutide's favorable fat-to-lean ratio holds in real-world use, outside the controlled conditions of clinical trials, will be a critical post-marketing question.

Hitaka et al. (2026) compared all three drugs' efficacy on MC4R-deficient obesity models, providing preclinical data suggesting the triple agonist approach may be particularly effective in patients with melanocortin pathway dysfunction.^[12]

Availability and Access

As of March 2026, only semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are FDA-approved and commercially available. Retatrutide remains investigational, with phase 3 TRIUMPH results expected throughout 2026 and potential FDA approval in late 2026 or 2027.

When retatrutide reaches the market, pricing and insurance coverage will determine whether the superior efficacy translates into widespread use. Eli Lilly manufactures both tirzepatide and retatrutide, which may influence how the two drugs are positioned relative to each other. Whether retatrutide is positioned as a first-line treatment or reserved for patients who do not achieve adequate weight loss on tirzepatide is a commercial and clinical decision that the TRIUMPH data will inform.

For patients currently choosing between available options, the SURMOUNT-5 data provide the most direct evidence: tirzepatide produces about 6.5 percentage points more weight loss than semaglutide, with a similar side effect profile. How much weight semaglutide produces and the context for choosing between available drugs are covered in the semaglutide results article.

What a Head-to-Head Retatrutide Trial Would Need

The absence of a direct retatrutide vs tirzepatide or semaglutide trial is the largest gap in the current evidence. Indirect comparisons through network meta-analyses can estimate relative efficacy, but they cannot account for differences in trial populations, inclusion criteria, background therapies, or measurement methods.

A well-designed head-to-head trial would need to enroll the same population (likely adults with BMI 30+ without diabetes), use the highest marketed doses of each drug, run for at least 72 weeks to capture plateau effects, and measure both weight and body composition (DXA). It would also need to assess patient-reported outcomes like quality of life and appetite, which are not captured by weight alone. Whether Eli Lilly would fund such a trial, given that they manufacture both tirzepatide and retatrutide, depends on commercial strategy rather than scientific necessity.

Until that trial exists, the comparison rests on indirect evidence. The consistent signal across network meta-analyses, narrative reviews, and pharmacological reasoning is that more receptor targets produce more weight loss. Whether that translates into better long-term health outcomes is a different question that will take years of post-marketing surveillance to answer.

The Bottom Line

Retatrutide, tirzepatide, and semaglutide form a clear efficacy hierarchy for weight loss: 28.7%, 20.2%, and 13.7% respectively, driven by their 3, 2, and 1 receptor targets. The only head-to-head trial (SURMOUNT-5) confirmed tirzepatide's superiority over semaglutide. No head-to-head trial exists for retatrutide against either drug. Safety profiles are broadly similar across the class, with gastrointestinal events dominating. Retatrutide's glucagon receptor component adds unique benefits for liver fat reduction and body composition that the other two drugs lack.

Frequently Asked Questions

Which is better for weight loss: retatrutide, tirzepatide, or semaglutide?

Based on clinical trial data, retatrutide produces the most weight loss (28.7% at 68 weeks), followed by tirzepatide (20.2% at 72 weeks) and semaglutide (13.7% at 72 weeks). The tirzepatide vs semaglutide comparison comes from a direct head-to-head trial (SURMOUNT-5, Aronne et al., 2025). The retatrutide comparison is indirect and based on separate trials with different populations.

Has retatrutide been compared head-to-head with Ozempic or Mounjaro?

No. As of March 2026, no head-to-head trial has directly compared retatrutide to either semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). The only head-to-head data comparing any two of these drugs is SURMOUNT-5, which tested tirzepatide against semaglutide. Retatrutide comparisons rely on indirect evidence from separate trials.

What makes retatrutide different from tirzepatide and semaglutide?

Retatrutide activates three hormone receptors (GLP-1, GIP, and glucagon) compared to two for tirzepatide (GLP-1, GIP) and one for semaglutide (GLP-1). The added glucagon receptor activation increases energy expenditure, promotes liver fat burning, and may improve the ratio of fat-to-lean mass loss. This glucagon component is what produces retatrutide's superior liver fat reduction and potentially better body composition outcomes.

Are the side effects of retatrutide worse than tirzepatide or semaglutide?

Gastrointestinal side effects (nausea, vomiting, diarrhea) are the primary concern across all three drugs and are broadly similar in severity. Retatrutide phase 3 data identified dysesthesia (abnormal touch sensations) as a new side effect affecting about 1 in 5 patients at the 12 mg dose, which has not been reported with tirzepatide or semaglutide. Heart rate increases were more pronounced with retatrutide but peaked and declined by 24 weeks.

When will retatrutide be available to prescribe?

Retatrutide is not yet FDA-approved. Phase 3 TRIUMPH results are expected throughout 2026, with a New Drug Application likely in 2026. If approved on a standard timeline, market availability could begin in 2027. Both semaglutide (Wegovy) and tirzepatide (Zepbound) are currently available for obesity treatment.

Is retatrutide better for fatty liver than semaglutide?

Clinical data strongly suggest yes. In a phase 2a trial by Sanyal et al. (2024), retatrutide produced dramatic liver fat reductions, with some patients achieving complete normalization. Targher et al. (2025) noted this exceeds what semaglutide or tirzepatide can achieve. The glucagon receptor component drives hepatic fat oxidation through a mechanism neither of the other two drugs possesses.